Frontiers in Medicine · 2020 · 16 citations · 38 references
MedicineOncologyPathologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer BiomarkersCancer ImmunotherapyEsophageal CancerGastric CancerImmune Checkpoint InhibitorsImmuno-oncology BiomarkersCd8+ Tumor-infiltrating LymphocytesCytotoxic T Lymphocyte InfiltrationDiagnostic ImmunohistochemistryImmunohistochemistry AssaysPd-l1 BlockadeProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerTissue Microarrays
Prognosis of gastric and esophageal cancer is poor and treatment improvements are needed. Programmed cell death 1 receptor (PD-1) interaction with its ligand PD-L1 in tumor micro-environment promotes immune tolerance and blocking monoclonal antibodies have entered clinical practice. However, clinical significance of PD-1 and PD-L1 expression in gastric and esophageal adenocarcinomas, particularly in non-Asian patients, is still unclear. Three tissue microarrays including 190 clinically annotated esophageal (n=31) and gastric (n=159) adenocarcinomas and 58 paired mucosa specimens, were stained with PD-1, PD-L1 and CD8-specific reagents in indirect immunohistochemistry assays. PD-L1 expression was detectable in 23.2% of cancer specimens. High PD-1 expression was detectable in 37.3% of cases and high CD8+ infiltration in 76%. PD-L1 and high PD1 expression significantly correlated with each other (rs=0.404, P<0.0001) and both significantly correlated with CD8+ infiltration (rs=0.435, P=0.0003 and rs=0.444; P=0.0004, respectively). CD8+ lymphocyte infiltration correlated with improved survival in univariate (P=0.009), but not multivariate analysis. Most interestingly, multivariate analysis and Kaplan-Meier curves indicate that combined low PD-1/PD-L1 expression and low CD8+ lymphocyte infiltration significantly correlate with poor prognosis. Our data document the clinical significance of a microenvironmental signature including PD-1/PD-L1 expression and CD8+ lymphocyte infiltration in gastric and esophageal adenocarcinomas and contribute to identify a patients’ subset requiring more aggressive peri-operative treatments.
38
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass, Vésteinn Thórsson, David Van Den Berg et al. · Nature · 2014 · 6.5K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17